Parkinson disease type 9
Other Names: Park 9; Pallidopyramidal degeneration with supranuclear upgaze paresis, and dementia; KRPPD; Kufor-Rakeb syndrome; Autosomal recessive Parkinson disease 9
Kufor–Rakeb syndrome is an autosomal recessive disorder of juvenile onset also known as Parkinson disease-9 (PARK9). Kufor-Rakeb syndrome (KRS) is a rare genetic neurodegenerative disorder characterized by juvenile Parkinsonism, pyramidal degeneration (dystonia), supranuclear palsy, and cognitive impairment.
It is associated with mutations in the ATP13A2 gene. This gene is located on the short arm of chromosome 1 .
There is considerable variation in the phenotype. For most diseases, symptoms will vary from person to person. People with the same disease may not have all the symptoms listed.
80%-99% of people have these symptoms
- Babinski sign
- Dementia(Dementia, progressive)
- Hyperreflexia in upper limbs
- Rigidity(Muscle rigidity)
- Slow saccadic eye movements(Slow eye movements)
30%-79% of people have these symptoms
- Abnormality of finger(Abnormalities of the fingers)
- Anarthria(Loss of articulate speech)
- Cerebral cortical atrophy(Decrease in size of the outer layer of the brain due to loss of brain cells)
- Difficulty in tongue movements
- Difficulty walking(Difficulty in walking)
- Dyskinesia(Disorder of involuntary muscle movements)
- Hypomimic face(Dull facial expression)
- Leg muscle stiffness
- Oculogyric crisis
- Short attention span(Poor attention span)
- Urinary incontinence(Loss of bladder control)
- Visual hallucinations
An ultrastructural study of the skin and muscle sample was carried out. Sequence analysis of all protein coding exons and exon-intron boundaries of genes was performed on patient's genomic DNA. A proprietary oligonucleotide-selective sequencing method was used for capturing genomic targets and sequencing was performed using Illumina sequencing system.
The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition.
- Apomorphine HCL (Brand name: Apokyn®)For the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose-wearing-off" and unpredictable :on/off" episodes) associated with advanced Parkinson's disease
|35x30px||This genetic disorder article is a stub. You can help Wikipedia by expanding it.|
NIH genetic and rare disease info
Parkinson disease type 9 is a rare disease.